<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536041</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-6950POU006</org_study_id>
    <nct_id>NCT01536041</nct_id>
  </id_info>
  <brief_title>A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Safety and Efficacy of ONO-6950 20 mg and 200 mg QD Versus Placebo and Montelukast (Singulair) in Asthmatic Patients Who Experience Exercise-induced Bronchoconstriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are:

      i. to determine the effect of single oral doses (20 and 200 mg) of ONO-6950 versus placebo on
      exercise induced bronchoconstriction (EIB) as percent attenuation in the decrease of forced
      expiratory volume in 1 second (FEV1) after exercise challenge

      ii. to determine the safety and tolerability of single dose administrations of 20 and 200 mg
      of ONO-6950 in asthmatic patients.

      The secondary objectives of this study are:

      i. to compare the effect of different (20 and 200 mg) single oral doses of ONO-6950 versus
      montelukast (10 mg) on EIB as percent attenuation in the decrease of FEV1 after exercise
      challenge

      ii. to determine the ratio of responders/non-responders in FEV1 for different (20 and 200 mg)
      single oral doses of ONO-6950 in comparison to montelukast (10 mg) and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will examine if ONO-6950 could alleviate EIB in asthmatic patients. Eligible
      patients will complete a randomized, double-blind, four-way crossover study. During each of
      four evaluation periods, patients will be administered a single dose of either 20 or 200 mg
      ONO-6950, 10 mg Montelukast, or placebo. Each evaluation period include various assessments
      following exercise challenge in an ambulatory setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of maximum fall in Forced Expiratory Volume in One Second (FEV1) after exercise</measure>
    <time_frame>60 minutes following the exercise challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-30 min)</measure>
    <time_frame>30 minutes following the exercise challenge</time_frame>
    <description>area under the concentration time curve integrating fall in FEV1 following exercise over the 30 minute interval immediately following exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-60 min)</measure>
    <time_frame>60 minutes following the exercise challenge</time_frame>
    <description>area under the concentration time curve integrating fall in FEV1 following exercise over the 60 minute interval immediately following exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of FEV1 to within 5% of the pre-exercise baseline</measure>
    <time_frame>90 minutes following the exercise challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients using a short acting beta agonist (rescue medication)</measure>
    <time_frame>90 minutes following the exercise challenge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of responder/non-responder in FEV1</measure>
    <time_frame>60 minutes following the exercise challenge</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Experimental 200 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 20 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-6950</intervention_name>
    <description>200 mg QD, single dose</description>
    <arm_group_label>Experimental 200 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-6950</intervention_name>
    <description>20 mg QD, single dose</description>
    <arm_group_label>Experimental 20 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg Montelukast, QD single dose</description>
    <arm_group_label>Active Comparator Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both genders, between 18 to 60 years of age, with bronchial asthma for at
             least 6 months and history of exercise induced bronchospasm

          -  Patients with FEV1 ≥ 70% of predicted after withholding short-acting β agonists for at
             least 8 hours prior to testing

          -  Screening exercise challenge demonstrates that the patient experiences a fall in FEV1
             of ≥ 20%

          -  Non-smokers with free from the usage of nicotine-containing products at least for a
             year prior to screening

        Exclusion Criteria:

          -  Previous history of life-threatening asthma, respiratory tract infection and/or
             exacerbation of asthma within 6 weeks prior to the first screening visit

          -  History of being unable to tolerate or complete an exercise challenge and clinically
             significant multiple drug or food allergies

          -  Past or present disorders and diseases including, but are not limited to
             cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric,
             endocrine, or pulmonary other than asthma

          -  Patients with Seasonal Allergic Rhinitis (SAR) or seasonal allergic asthma,with
             significant symptoms that may confound study assessment

          -  Significant safety laboratory, ECG, or vital sign abnormalities that would place the
             patient at undue risk during the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ono Pharma USA, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Clinical Site 110</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Site 140</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Clinical Site 160</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Dartmouth Clincial Site 150</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinical Site 190</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Clinical Site 170</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Clinical Site 130</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Braunfeis Clinical Site 120</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Clinical Site 180</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <disposition_first_submitted>January 21, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 21, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 14, 2014</disposition_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>Adult</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

